newsfilter
← Latest News
Business Wire·

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

- Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP